黛力新对心肌梗死后心衰患者焦虑的疗效及血清因子的影响  

Curative effect of Deanxit on anxiety of patients with heart failure after acute myocardial infarction and influence on serum factors

作　　者：沈艳[1] 阮长武[1] 魏盟[2] 

机构地区：[1]上海市第八人民医院心内科,上海200235 [2]上海交通大学附属第六人民医院心内科

出　　处：《西南国防医药》2014年第12期1283-1286,共4页Medical Journal of National Defending Forces in Southwest China

基　　金：国家自然科学基金(81070110)

摘　　要：目的探讨黛力新对急性心肌梗死(AMI)后心力衰竭伴焦虑、抑郁患者临床症状及内皮素-1(ET-1)、人纤溶酶原激活物抑制因子-1(PAI-1)、血管紧张素Ⅱ(AngⅡ)水平的影响。方法将80例AMI心力衰竭伴焦虑、抑郁患者随机分为观察组及对照组各40例,对照组给予潘立酮治疗,观察组在对照组基础上给予黛力新治疗,观察两组治疗效果及治疗前后汉密尔顿焦虑量表(HAMA)评分、汉密尔顿抑郁量表(HAMD)评分变化;彩色多普勒超声心动图测量患者心搏量(SV)、心输出量(CO)、射血分数(EF);治疗前后应用ELISA法测定两组血清ET-1、PAI-1及AngⅡ水平。结果观察组总有效率为95.00%,对照组总有效率为75.00%,差异有统计学意义(P<0.05);观察组治疗后HAMA、HAMD评分和血清ET-1、PAI-1、AngⅡ水平均显著低于对照组(P<0.01);观察组治疗后SV、CO、EF水平显著高于对照组,而左心室舒张早期/晚期速度峰值比值(VA/VE)低于对照组(P<0.05或P<0.01)。结论黛力新能有效改善AMI心力衰竭伴焦虑、抑郁患者临床症状,降低患者ET-1、PAI-1、AngⅡ水平,改善心功能,提高治疗效果。Objective To explore the effects of Deanxit on clinical symptoms of anxiety and depression and the level of endothclin-1 （ ET-1 ）, human plasminogen activator inhibitor-1 （PAI-1） and angiotensin Ⅱ （ Ang Ⅱ） of patients after acute myocardial infarction （AMI）. Methods Total 80 patients with heart failure associated with anxiety and depression after AMI were randomlydivided into observation group and control group （n = 40, respectively）. The control group was provided with Iloperidone, while the observation group was provided with Deanxit in addition to Iloperidone. The curative effects and the changes of Hamilton Anxiety Scale （HAMA） score and Hamilton Depression Scale （HAMD） score of the patients in both groups before and after the treatment were observed and compared each other. And then, color Doppler eehocardiography was used to measure the stroke volume （SV）, cardiac output （CO） ,and ejection fraction （EF） of the patients. Before and after the treatment,ELISA method was used to determine the levels of serum ET-1 ,PAI-1 and Ang Ⅱ in both groups. Results The difference of total treatment efficiency between the observation group （95%） and the control group （75%） was statistically significant （P 〈 0.05 ）. After treatment, the HAMA and HAMD scores as well as levels of serum ET-1, PAI-1, and Ang II of the observation group were significantly lower than those of the control group （ P 〈 0.01 ） ;SV, CO, and EF of the observation group were significantly higher than those of the control group, and the early/ late peak velocity ratio of the left ventricular diastolic function （ VA/VE ） was significantly lower than that of the control group （ P 〈 0.05 or P 〈 0.01 ）. Conclusion Deanxit can effectively improve the clinical symptoms of patients with heart failure associated with anxiety and depression after AMI, reduce the levels of ET-1, PAI-1 and Ang Ⅱ of the patients, and improve the heart function as well as the treatment effect.

关 键 词：黛力新 焦虑 抑郁 内皮素-1 人纤溶酶原激活物抑制因子-1 血管紧张素Ⅱ 

分 类 号：R541.4[医药卫生—心血管疾病]